Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cytokinetics Presents Additional Results From SEQUOIA-HCM In Late Breaking Clinical Trial Session At European Society Of Cardiology Heart Failure 2024 Congress

Author: Benzinga Newsdesk | May 13, 2024 09:34am

Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten

Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongly Correlated to Other Measures of Clinical Improvement

 

Posted In: CYTK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)
CORE Finalist